Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin, Poly ICLC, and radiation in advanced CTCL
NCT02061449Phase 1Terminated
- Sponsor
- NYU Langone Health
- Start
- Mar 2014
- Primary completion
- Nov 2018
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of poly iclc in mycosis fungoides (MF), sponsored by NYU Langone Health. Started Mar 2014; status: terminated.
02
Drugs
poly iclc
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT02061449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061449.